This finding supported the idea that TGF‐β1 is the critical target of PFD and that PFD plays an antitumour role by targeting TGF‐β1 to inhibit glycolysis and EMT in lung adenocarcinoma, especially in NSCLC with a highly metabolic phenotype. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.